Puerarin attenuated early diabetic kidney injury through down-regulation of matrix metalloproteinase 9 in streptozotocin-induced diabetic rats

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Zhong, Yifei ^a   Zhang, Xianwen ^a   Cai, Xianfan ^a   Wang, Ke ^b   Chen, Yiping ^a   Deng, Yueyi ^a  

^a LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b National Engineering Research Center for Biochip at Shanghai   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; COLLAGEN TYPE 4; GELATINASE B; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LOSARTAN; NEPHRIN; PODOCIN; PROTEIN; PUERARIN; REACTIVE OXYGEN METABOLITE;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME REPRESSION; GAPDH GENE; GENE; GLUCOSE BLOOD LEVEL; KIDNEY; KIDNEY HYPERTROPHY; MALE; MMP 9 GENE; NEPHRIN GENE; NITROSYLATION; NONHUMAN; ONSET AGE; PODOCIN GENE; PODOCYTE; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; URINARY EXCRETION;

ANIMALS; COLLAGEN TYPE IV; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EVALUATION, PRECLINICAL; ENZYME REPRESSION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOFLAVONES; KIDNEY; LOSARTAN; MALE; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; PODOCYTES; PROTEINURIA; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; STREPTOZOCIN;

EID: 84898652796     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085690     Document Type: Article

References (52)

1. Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes mellitus. The New Engla (Pubitemid 29466226)
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensinconvertingenzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462. (Pubitemid 23335891)
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860.
4. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869.
5. Parving HH, Chaturvedi N, Viberti G, Mogensen CE (2002) Does microalbuminuria predict diabetic nephropathy? Diabetes Care 25:406-407.
6. Rossing P, Hommel E, Smidt UM, Parving HH (1993) Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42:715-719. (Pubitemid 23127162)
7. Ijpelaar DH, Schulz A, Koop K, Schlesener M, Bruijn JA, et al. (2008) Glomerular hypertrophy precedes albuminuria and segmental loss of podoplanin in podocytes in Munich-Wistar-Fromter rats. American journal of physiology Renal physiology 294:F758-767.
8. Meyer TW, Bennett PH, Nelson RG (1999) Podocyte number predicts longterm urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 42:1341-1344. (Pubitemid 29500971)
9. Steffes MW, Schmidt D, McCrery R, Basgen JM (2001) Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 59:2104-2113. (Pubitemid 32467602)
10. Dunlop M (2000) Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney international Supplement 77:S3-12.
11. Forbes JM, Cooper ME, Oldfield MD, Thomas MC (2003) Role of advanced glycation end products in diabetic nephropathy. Journal of the American Society of Nephrology: JASN 14:S254-258. (Pubitemid 36903936)
12. Araki S, Ng DP, Krolewski B, Wyrwicz L, Rogus JJ, et al. (2003) Identification of a common risk haplotype for diabetic nephropathy at the protein kinase C-beta1 (PRKCB1) gene locus. Journal of the American Society of Nephrology: JASN 14:2015-2024. (Pubitemid 36909909)
13. Schleicher ED, Weigert C (2000) Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney international Supplement 77:S13-18.
14. Susztak K, Bottinger E, Novetsky A, Liang D, Zhu Y, et al. (2004) Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 53:784-794. (Pubitemid 38270650)
15. Bai Y, Wang L, Li Y, Liu S, Li J, et al. (2006) High ambient glucose levels modulates the production of MMP-9 and alpha5 (IV) collagen by cultured podocytes. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 17:57-68.
16. Noriega-Cisneros R, Cortes-Rojo C, Manzo-Avalos S, Clemente-Guerrero M, Calderon-Cortes E, et al. (2013) Mitochondrial response to oxidative and nitrosative stress in early stages of diabetes. Mitochondrion.
17. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, et al. (2002) S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297:1186-1190. (Pubitemid 36193354)
18. Lelongt B, Legallicier B, Piedagnel R, Ronco PM (2001) Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases? Current opinion in nephrology and hypertension 10:7-12. (Pubitemid 32102216)
19. Fernandez D, Larrucea S, Nowakowski A, Pericacho M, Parrilla R, et al. (2011) Release of podocalyxin into the extracellular space. Role of metalloproteinases. Biochim Biophys Acta 1813:1504-1510.
20. Liu S, Liang Y, Huang H, Wang L, Li Y, et al. (2005) ERK-dependent signaling pathway and transcriptional factor Ets-1 regulate matrix metalloproteinase-9 production in transforming growth factor-beta1 stimulated glomerular podocytes. Cell Physiol Biochem 16:207-216. (Pubitemid 41643020)
21. Asanuma K, Shirato I, Ishidoh K, Kominami E, Tomino Y (2002) Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes. Kidney Int 62:822-831. (Pubitemid 35316711)
22. Von Luttichau I, Djafarzadeh R, Henger A, Cohen CD, Mojaat A, et al. (2002) Identification of a signal transduction pathway that regulates MMP-9 mRNA expression in glomerular injury. Biol Chem 383:1271-1275. (Pubitemid 35215077)
23. Okada R, Kawai S, Naito M, Hishida A, Hamajima N, et al. (2012) Matrix metalloproteinase-9 gene polymorphisms and chronic kidney disease. Am J Nephrol 36:444-450.
24. Hirakawa S, Lange EM, Colicigno CJ, Freedman BI, Rich SS, et al. (2003) Evaluation of genetic variation and association in the matrix metalloproteinase 9 (MMP9) gene in ESRD patients. Am J Kidney Dis 42:133-142. (Pubitemid 36807662)
25. Lian S, Wang L, Zhang X, Wang N, Tang H, et al. (2010) Clinical investigation of stage-IV diabetic nephropathy with treatment of Chen's Tangshen decoction and conventional Western medicine. Shanghai Jouranl of Traditional Chinese Medicine 44:3.
26. Liu R, Xing D, Lu H, Wu H, Du L (2006) Pharmacokinetics of puerarin and ginsenoside Rg1 of CBN injection and the relation with platelet aggregation in rats. The American journal of Chinese medicine 34:1037-1045. (Pubitemid 44921248)
27. Zhang XW, Deng YY, Chen YP, Zhong YF (2009) High blood glucose level modulates MMP-9 mRNA and protein in the kidney of Wistar rats. Theory and practice of diagnosis 8:4.
28. Osicka TM, Yu Y, Panagiotopoulos S, Clavant SP, Kiriazis Z, et al. (2000) Prevention of albuminuria by aminoguanidine or ramipril in streptozotocininduced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 49:87-93. (Pubitemid 30022928)
29. Koop K, Eikmans M, Baelde HJ, Kawachi H, De Heer E, et al. (2003) Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 14:2063-2071. (Pubitemid 36909914)
30. Hammond JB, Kruger NJ (1988) The bradford method for protein quantitation. Methods in molecular biology 3:25-32.
31. Rossing P (2013) Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted? Nat Rev Nephrol 9:128-130.
32. Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, et al. (2012) Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 23:123-130.
33. Yang W, Lu J, Weng J, Jia W, Ji L, et al. (2010) Prevalence of diabetes among men and women in China. N Engl J Med 362:1090-1101.
34. Jia W, Gao X, Pang C, Hou X, Bao Y, et al. (2009) Prevalence and risk factors of albuminuria and chronic kidney disease in Chinese population with type 2 diabetes and impaired glucose regulation: Shanghai diabetic complications study (SHDCS). Nephrol Dial Transplant 24:3724-3731.
35. Mogensen CE, Hansen KW, Nielsen S, Pedersen MM, Rehling M, et al. (1993) Monitoring diabetic nephropathy: glomerular filtration rate and abnormal albuminuria in diabetic renal disease-reproducibility, progression, and efficacy of antihypertensive intervention. American journal of kidney diseases: the official journal of the National Kidney Foundation 22:174-187. (Pubitemid 23203516)
36. Lahdenkari AT, Lounatmaa K, Patrakka J, Holmberg C, Wartiovaara J, et al. (2004) Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria. Journal of the American Society of Nephrology: JASN 15:2611-2618. (Pubitemid 41103367)
37. Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, et al. (1996) Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39:1569-1576. (Pubitemid 26397369)
38. Duan HJ, Liu SX, Zhang YJ, Liu QJ, He N, et al. (2004) [Effects of puerarin on renal function, expressions of MMP-2 and TIMP-2 in diabetic rats]. Yao xue xue bao = Acta pharmaceutica Sinica 39:481-485. (Pubitemid 39586385)
39. Wu L, Qiao H, Li Y, Li L (2007) Protective roles of puerarin and Danshensu on acute ischemic myocardial injury in rats. Phytomedicine: international journal of phytotherapy and phytopharmacology 14:652-658. (Pubitemid 47419302)
40. Zhang H, Liu Y, Lao M, Ma Z, Yi X (2011) Puerarin protects Alzheimer's disease neuronal cybrids from oxidant-stress induced apoptosis by inhibiting prodeath signaling pathways. Experimental gerontology 46:30-37.
41. Kataya HA, Hamza AA (2008) Red Cabbage (Brassica oleracea) Ameliorates Diabetic Nephropathy in Rats. Evidence-based complementary and alternative medicine: eCAM 5:281-287.
42. Choi YE, Ahn SK, Lee WT, Lee JE, Park SH, et al. (2010) Soybeans ameliolate diabetic nephropathy in rats. Evidence-based complementary and alternative medicine: eCAM 7:433-440.
43. Wang GG, Lu XH, Li W, Zhao X, Zhang C (2011) Protective Effects of Luteolin on Diabetic Nephropathy in STZ-Induced Diabetic Rats. Evidencebased complementary and alternative medicine: eCAM 2011:323171.
44. Wan Y, Gu L, Suzuki K, Karasawa T, Fujioka Y, et al. (2005) Multi-glycoside of Tripterygium wilfordii Hook f. ameliorates proteinuria and acute mesangial injury induced by anti-Thy1.1 monoclonal antibody. Nephron Experimental nephrology 99:e121-129.
45. Dong DC, Zhou LF, Chen JX (1987) [Changes in proteinuria, renal function and immunity after treatment with injections of a solution of Astragalus membranaceus]. Zhong xi yi jie he za zhi= Chinese journal of modern developments in traditional medicine/Zhongguo Zhong xi yi jie he yan jiu hui 7:403-404, 388.
46. Vu TH, Werb Z (2000) Matrix metalloproteinases: effectors of development and normal physiology. Genes & development 14:2123-2133.
47. Lelongt B, Trugnan G, Murphy G, Ronco PM (1997) Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro. The Journal of cell biology 136:1363-1373. (Pubitemid 27421921)
48. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, et al. (1998) MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93:411-422. (Pubitemid 28232085)
49. Dubois B, Masure S, Hurtenbach U, Paemen L, Heremans H, et al. (1999) Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. The Journal of clinical investigation 104:1507-1515. (Pubitemid 30002362)
50. Andrews KL, Betsuyaku T, Rogers S, Shipley JM, Senior RM, et al. (2000) Gelatinase B (MMP-9) is not essential in the normal kidney and does not influence progression of renal disease in a mouse model of Alport syndrome. The American journal of pathology 157:303-311. (Pubitemid 30641746)
51. Liu Y (2006) Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69:213-217. (Pubitemid 43323069)
52. Kluger MA, Zahner G, Paust HJ, Schaper M, Magnus T, et al. (2013) Leukocyte-derived MMP9 is crucial for the recruitment of proinflammatory macrophages in experimental glomerulonephritis. Kidney Int 83:865-877.